- AGC Biologics has expanded its manufacturing agreement with South Korea-based Novelty Nobility to support process development and GMP manufacturing of NN4101 in Japan.
- The bispecific antibody candidate for neovascular retinal diseases will move to AGC Biologics’ Chiba facility following earlier cell line development work in Denmark.
AGC Biologics has expanded its manufacturing agreement with South Korea-based biotech company Novelty Nobility to support the development of NN4101, a bispecific antibody drug candidate for neovascular retinal diseases. Under the agreement, AGC Biologics will provide process development and GMP manufacturing services at its Chiba, Japan facility.
The collaboration follows an earlier partnership between the two companies and builds on work already completed within AGC Biologics’ global network. According to the companies, cell line development for the program was completed in Copenhagen, Denmark, with the project now progressing to technology transfer and manufacturing activities in Japan.
NN4101 is described as a first-in-class bispecific antibody that combines a fully human anti-c-Kit monoclonal antibody with a vascular endothelial growth factor (VEGF) trap. The candidate is being developed for the treatment of neovascular retinal diseases.
“AGC Biologics has proven to be an ideal manufacturing partner for advancing our most complex programs. Their seamless global network — from cell line development to GMP manufacturing — gives us the confidence to move NN4101 forward with speed and precision.”
Sang Gyu Park, CEO of Novelty Nobility
The agreement also highlights AGC Biologics’ broader expansion plans in Japan. The company stated that its new Yokohama facility will provide large-scale GMP manufacturing capacity using single-use bioreactor technology, supporting future demand for biologics and contract manufacturing services globally.
